Skip to main content
. Author manuscript; available in PMC: 2019 Oct 7.
Published in final edited form as: Breast Cancer Res Treat. 2018 Jun 25;171(3):637–648. doi: 10.1007/s10549-018-4852-5

Fig. 3.

Fig. 3

Targeted DNA sequencing mutations and copy number alterations. a Significantly mutated genes (SMGs) across all available tissues, b mutations in the PI3K/mTOR pathway, c HER2 Copy Number Variations (CNVs) versus Intracranial Time to Progression in brain metastases, d HER2 CNVs versus Overall Survival across all available tissues. Dotted line is the correlation based on the primary tumors only. Horizontal lines indicate tissues from matched pairs (n = 2)